Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: Association with oligoclonal IgM bands and prediction of Multiple Sclerosis diagnosis-Reference-Cited by-同舟云学术

Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: Association with oligoclonal IgM bands and prediction of Multiple Sclerosis diagnosis

Published:2015-06 Issue: Volume:283 Page:64-69
ISSN:0165-5728
Container-title:Journal of Neuroimmunology
language:en
Short-container-title:Journal of Neuroimmunology

Author:

Ferraro Diana,Galli Veronica,Vitetta Francesca,Simone Anna Maria,Bedin Roberta,Del Giovane Cinzia,Morselli Franca,Filippini Maria Maddalena,Nichelli Paolo Frigio,Sola Patrizia

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,Immunology,Immunology and Allergy

Reference35 articles.

1. CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions;Alvarez;Mult. Scler.,2013

2. CXC chemokine ligand 13 plays a role in experimental autoimmune encephalomyelitis;Bagaeva;J. Immunol.,2006

3. The risk of relapse after a clinically isolated syndrome is related to the pattern of oligoclonal bands;Boscá;J. Neuroimmunol.,2010

4. The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS);Brettschneider;PLoS One,2010

5. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis;Corcione;Proc. Natl. Acad. Sci. U. S. A.,2004

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic relevance of the C‐X‐C motif chemokine ligand 13 and interleukin‐8 in predicting the transition from clinically isolated syndrome to multiple sclerosis;European Journal of Neuroscience;2024-03-07

2. Blood-brain barrier damage associates with glia-related cytokines in the cerebrospinal fluid of patients with Multiple Sclerosis;Multiple Sclerosis and Related Disorders;2024-02

3. Neurodegeneration and its potential markers in the diagnosing of secondary progressive multiple sclerosis. A review;Frontiers in Molecular Neuroscience;2023-09-12

4. Protein biomarkers in multiple sclerosis;encephalitis;2023-04-10

5. IgM to phosphatidylcholine in multiple sclerosis patients: from the diagnosis to the treatment;Therapeutic Advances in Neurological Disorders;2023-01